Načítá se...
Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib
Sorafenib is an oral tyrosine kinase inhibitor (TKI) that acts on many targets including RAF kinases, vascular endothelial growth factor (VEGF) 1, 2, 3, platelet derived growth factor and c-kit receptor and is currently FDA approved for unresectable hepatocellular carcinoma (HCC). Trebananib (AMG 38...
Uloženo v:
| Vydáno v: | J Gastrointest Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Pioneer Bioscience Publishing Company
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4226824/ https://ncbi.nlm.nih.gov/pubmed/25436132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2014.049 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|